Background: While high-sensitivity C-reactive protein (hsCRP) is an independent predictor of cardiovascular risk, global risk prediction use.
T he Framingham risk model (1) is used extensively for detecting risk for coronary heart disease and has been adapted by the Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program (2) . The traditional risk factors included are strong predictors of cardiovascular risk, and the model has been validated in several populations (3) . However, despite the model's success, up to 20% of all coronary events occur in the absence of any major risk factor (4, 5) . In addition, most individuals who do not develop coronary heart disease have at least 1 clinically elevated Framingham risk factor (6) .
Given these modest levels of sensitivity and specificity, research over the past decade has focused on novel bloodbased atherosclerotic risk factors that, like cholesterol, can be inexpensively obtained and interpreted in the primary care setting. One of the most promising of these is highsensitivity C-reactive protein (hsCRP), a biomarker of inflammation that has consistently been shown to predict incident myocardial infarction, stroke, and cardiovascular death among apparently healthy men and women after adjustment for all components of the Framingham risk score (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . Blood levels of hsCRP also correlate with hypofibrinolysis and abnormal glucose metabolism, and thus reflect pathophysiologic processes that are related to vascular occlusion but are not easily measured with traditional risk factors (17) (18) (19) (20) . On that basis, in 2003 the Centers for Disease Control and Prevention and the American Heart Association published the first set of guidelines to endorse the use of hsCRP as a potential adjunct to traditional risk factor screening (21) .
Despite these data, no simple clinical algorithm that includes Framingham covariables and hsCRP has been developed, and thus it has not been possible to determine whether individuals might be more accurately classified if hsCRP were added to global risk prediction models for major cardiovascular disease (CVD), including myocardial infarction, coronary revascularization, stroke, and cardiovascular death (22) .
METHODS
We compared the clinical utility of global cardiovascular risk prediction models based on Framingham covariables with and without hsCRP among participants in the Women's Health Study (WHS) (23) (24) (25) , a large-scale, nationwide cohort of U.S. women age 45 years and older who were free of CVD and cancer at study entry. Women were followed annually for the development of CVD, with an average follow-up of 10 years. All reported CVD outcomes, including myocardial infarction, ischemic stroke, coronary revascularization procedures, and deaths from cardiovascular causes, were adjudicated by an end points committee after medical record review. All study participants provided written informed consent, and the study protocol was approved by the institutional review board of Brigham and Women's Hospital in Boston, Massachusetts.
Baseline blood samples were assayed for C-reactive protein with a validated, high-sensitivity assay (Denka Seiken, Tokyo, Japan) and for total, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol with direct-measurement assays (Roche Diagnostics, Basel, Switzerland). Women who were diabetic at baseline were excluded from predictive modeling because ATP III labeling considers diabetes to be a risk equivalent for coronary heart disease (2). In parallel with guidelines established for lipid evaluation (26) , models were initially fitted in a derivation cohort limited to women not taking hormone replacement therapy at baseline (n ϭ 15 048 with data on all variables) and were then applied to all nondiabetic women (n ϭ 26 927) for clinical risk prediction.
Development of Risk Prediction Models
Models were fitted by using Cox proportional hazards models (27) , restricting predictors to components of the Framingham risk score (including either total or LDL cholesterol as well as HDL cholesterol), and adding hsCRP. To determine the functional form used for each predictor, we examined spline plots and fitted power functions to determine the best fit for each variable. When fit was similar, we chose the simplest form, usually a linear term or log transformation, especially when supported by previous data from existing ATP III algorithms.
To model blood pressure more fully, we included a nonlinear term for systolic blood pressure. As in the Framingham score, we included antihypertensive medication use and considered its interaction with blood pressure. At baseline in the WHS, use of cholesterol-lowering medications was rare, was not composed of statins, and was not statistically significant in these models. As also in the Framingham score, current but not past smoking was included. We considered interactions of all predictors with smoking and age, particularly on the basis of inclusion in the ATP III risk score. To enhance model simplicity, these were not included when they were only of marginal statistical significance. Of interest, when body mass index was added to the final model, it was not a statistically significant predictor of CVD in these data, an observation consistent with its absence from the Framingham risk score.
In addition to comparing the performance of the final model derived from the WHS data with hsCRP to the WHS model without hsCRP, we also compared the performance of the formal ATP III model (2), with and without hsCRP (Appendix, available at www.annals.org). The ATP III model includes terms for the natural logarithms of age, of total and HDL cholesterol, and of systolic blood pressure and was developed for the prediction of "hard" coronary heart disease events, including myocardial infarction and death from coronary heart disease. Total CVD, including ischemic stroke as well as revascularization procedures, was used as the end point in these analyses. To be conservative and allow the best possible fit for all traditional covariables, we recalculated ␤-coefficients for the ATP III model in the WHS data before evaluating any additive effects of hsCRP.
Measures of Model Fit
The primary means of comparing predictive models based on Framingham covariables with and without hsCRP was the Bayes information criterion, a likelihood-based measure that adds a penalty for model complexity (28, 29) . Lower values indicate better fit. Because of its common use in the medical literature, we also computed the c-index (28), or concordance probability, which is a generalization of the c-statistic, or the area under the receiver-operating characteristic curve (30) , that allows for censored data. For these analyses, the c-index was computed and adjusted for optimism due to overfitting with bootstrap sampling (31)
Context
The value of adding high-sensitivity C-reactive protein (hsCRP) to a global risk assessment model is unknown.
Contribution
The authors used the Women's Health Study, a nationwide cohort of 15 048 initially healthy women, to develop a cardiovascular disease (CVD) risk prediction model using hsCRP and Framingham risk model predictors. While hsCRP improved overall model fit, the clinical utility of hsCRP in terms of reclassification was most substantial for those with a 5% or greater 10-year risk based on traditional risk factors.
Cautions
The study does not address the clinical value of lowering hsCRP level.
Implications
In this largely low-risk population, adding hsCRP to the Framingham model reclassified patients into groups that better reflected their actual CVD risk. This effect was most clinically relevant for those at intermediate risk.
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Article Risk Prediction Models with and without hsCRP using the Design library in S-PLUS software (Insightful Corp., Seattle, Washington) (28) .
For comparison, we also computed several other measures of global model fit (provided in the Appendix, available at www.annals.org), including other likelihood-based measures such as model weights for the Bayes information criterion, which provide an estimate of the posterior probability of each model given the set of candidate models considered (29, 32) ; the Akaike information criterion and its corresponding model weights (32) ; and Nagelkerke's generalized model R 2 (33, 34) . We computed the D-statistic of Royston and Sauerbrei (35) , based on the separation of survival curves by predictor variables, and again adjusted for optimism. Differences in statistics between nested models were tested with a 1-sided test using bootstrap sampling (31) . We also calculated the Brier score (28) , which directly compares the observed outcomes with the fitted probabilities.
To assess model calibration, or how closely the predicted probabilities reflect actual risk, observed risk was calculated on the basis of 8 years of follow-up (available for all participants) and was extrapolated to 10 years for display purposes. We computed the Hosmer-Lemeshow calibration statistic (36) comparing observed and predicted risk using 10 categories based on 2-percentage point increments in predicted risk, ranging from less than 2% to 18% or greater. We also computed this statistic using decile categories of predicted probabilities.
To address clinical utility, we directly compared predicted risk estimates that are based on models using Framingham covariables with and without hsCRP with actual risk that was observed during study follow-up among all 26 927 women for whom data were available. We used weighted statistics (37) to compare the predicted probabilities with and without hsCRP. To approximate clinical criteria commonly used in current treatment guidelines (2, 38), we grouped the predicted probabilities into 10-year risk categories of 0% to less than 5%, 5% to less than 10%, 10% to less than 20%, and 20% or greater.
Finally, to address the generalizability of the final WHS risk prediction model with hsCRP, we calibrated the predicted probabilities to observed risk in the Framingham Heart Study, using a limited-access data set available from the National Heart, Lung, and Blood Institute at www .nhlbi.nih.gov/resources/deca/default.htm. Mean values Risk estimates are provided on a natural log scale and were derived from a Cox regression model using a flexible spline curve. Dotted lines represent 95% CIs.
among women age 47 years and older at the 10th Framingham examination were evaluated. Mean HDL cholesterol level at the 10th examination was estimated on the basis of age and HDL cholesterol level at the 15th examination. The population mean hsCRP value was estimated from a model derived from the WHS, including the other risk factors plus body mass index. The average 10-year risk for major CVD in the Framingham data, including myocardial infarction, stroke, and cardiovascular death, was estimated by using a product-limit estimator. The projected This scoring system is intended as an illustration only. CVD ϭ cardiovascular disease; HDL ϭ high-density lipoprotein; RR ϭ relative risk; SBP ϭ systolic blood pressure. To convert cholesterol values to mmol/L, multiply by 0.02586.
10-year risk from the WHS models was calibrated to the 10-year rate of cardiovascular outcomes among women in the Framingham data (Appendix, available at www.annals.org).
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This work was supported by grants from the Donald W. Reynolds Foundation, the Leducq Foundation, the Doris Duke Charitable Foundation, and the National Institutes of Health. The funding agencies had no role in the design, conduct, or reporting of the study or in the decision to submit the manuscript for publication. The best-fitting global cardiovascular risk prediction model in these data included all Framingham covariables and hsCRP ( Table 1 ). Figure 1 shows that after adjustment for all Framingham variables, there was a log-linear relationship between hsCRP and risk for CVD. While risk estimates based on the model coefficients given in Table 1 provide the best estimates, for clinical utility we also calculated a point scoring system (39) for cardiovascular risk analogous to that used by the National Cholesterol Education Program (Figure 2) . The absolute risk estimates in Figure 2 are calibrated to the overall incidence in the Framingham Heart Study sample to enhance generalizability.
RESULTS
Relative Contributions to Global Risk of Age, Blood Pressure, Smoking, Lipids, and hsCRP Table 2 presents a comparison of the relative contributions to global risk made by each individual Framingham covariate and by hsCRP. Age is the strongest predictor of risk in these data, leading to a high likelihood ratio and a c-index of 0.73. After adjustment for age, likelihood ratio statistics demonstrated the strongest improvement in fit for systolic blood pressure, followed in descending order by hsCRP; current smoking; and HDL, total, and LDL cholesterol. In models that included age, systolic blood pressure, and current smoking (the 3 strongest predictors in aggregate), likelihood ratio statistics similarly demonstrated the strongest fit for hsCRP, followed in order by HDL, total, and LDL cholesterol. Table 2 also demonstrates the relative insensitivity of the c-index as a method of determining model fit. For example, while the likelihood ratio statistic was able to rank the relative contributions of systolic blood pressure, hsCRP, smoking, and HDL cholesterol in the age-adjusted analyses, the c-index had little ability to distinguish among any of these (all values between 0.75 and 0.77). Similarly, in the analyses adjusted for age, systolic blood pressure, and smoking, the likelihood ratio statistic indicated that either hsCRP or HDL cholesterol improved fit more than did total or LDL cholesterol, yet the c-index was again unable to distinguish between these measures (all values 0.80).
Discrimination and Calibration in Models with and without hsCRP
For both the ATP III model and the final WHS model, the likelihood ratio test for the inclusion of hsCRP was highly significant (P Ͻ 0.001). Of note, the Bayes information criterion indicated a strong preference for the inclusion of hsCRP ( Table 1) after adjustment for adding a variable. This suggests that the model including hsCRP provided better fit, even after adjustment for the increase in number of predictors. Similarly, models that included hsCRP demonstrated better calibration (higher P value for calibration), while models without hsCRP had larger deviations between the observed and predicted probabilities in the higher-risk categories (Figure 3) . By contrast, the c- index again showed minimal ability to detect differences in model fit. As shown in the Appendix Table (available at  www. annals.org), all global measures of fit showed improvement when hsCRP was added to prediction models based on Framingham covariables alone.
Clinical Risk Classification and Accuracy
To better compare model performance within clinical categories, we classified all nondiabetic women (n ϭ 26 927) into 4 risk groups defined by the ATP III categories of 10-year risk for CVD of 0% to less than 5%, 5% to less than 10%, 10% to less than 20%, and 20% or greater. We then compared the WHS models with and without hsCRP by cross-classifying expected risks and comparing these to the observed proportions of events in each group. While there was general agreement between these classifications (weighted ϭ 0.86), the predicted risk categories changed substantially with the addition of hsCRP for women with at least a 5% 10-year risk according to only the Framingham risk variables (Table 3) . Specifically, more than 20% of all participants with intermediate risk were reclassified with the addition of hsCRP; among those originally classified as having 5% to less than 10% risk, 12% moved down a category in risk and 10% moved up. Among those originally classified as having 10% to less than 20% risk, 19% were reclassified: 14% to a lower and 5% to a higher category. Among those at high risk (Ն20% risk), 14% were reclassified into a lower-risk category. By contrast, among those with less than 5% risk according to Framingham covariables, only 2% were reclassified. Thus, overall in this low-risk cohort, with 88% of women in the lowest risk group, 4% were reclassified. However, this overall percentage depends heavily on the underlying risk and would be substantially greater in an older or higherrisk population. For comparison, according to ATP III risk categories based on National Cholesterol Education Program ␤-coefficients rather than those derived from the Article Risk Prediction Models with and without hsCRP WHS, among women originally classified as having less than 5%, 5% to less than 10%, 10% to less than 20%, and 20% or greater 10-year risk, 4%, 38%, 42%, and 20%, respectively, were reclassified in the WHS model that included hsCRP.
Of note, for women reclassified, the models that included hsCRP also estimated the actual risk more accurately. For example, among those classified in the 5% to less than 10% category according to the model without hsCRP, the 12% reclassified to the lower-risk category actually experienced only a 2% risk, and the 10% reclassified to a higher-risk category actually experienced a higher 15% risk ( Table 3 ). The addition of hsCRP also led to better calibration for women initially classified into the other 3 groups.
DISCUSSION
The Framingham risk score provides a useful measure of risk stratification for coronary heart disease and has been valuable in clinical practice. Whether it can be improved by including other simple and inexpensive measures has not previously been determined. We fitted predictive models for major CVD, including myocardial infarction, coronary revascularization, stroke, and cardiovascular death, using traditional Framingham predictors, with and without the addition of hsCRP. As shown, all global measures of predictive accuracy were improved in prediction models that included hsCRP. In particular, likelihood-based measures showed a strong preference for the models with hsCRP, and the Bayes information criterion weights, corresponding to the posterior model probabilities, strongly supported the addition of hsCRP. As also shown in these data, the relative contribution to global risk made by hsCRP was at least as large as that made by total, HDL, or LDL cholesterol. The added predictive value of including hsCRP was most evident among those at 5% or greater 10-year risk.
While all the likelihood-based measures of fit improved when hsCRP was added, the c-index, or generalized c-statistic, changed little with the addition of any bloodbased risk factor (including total, HDL, and LDL cholesterol) once we accounted for age, smoking, and blood pressure. In fact, the increase in the c-index associated with hsCRP was greater than that for any of the lipids. This observation underscores the limitations of the c-index, or area under the receiver-operating characteristic curve, as a method for determining model fit, despite its continued popular use in the medical literature. The c-index is particularly suited to retrospective case-control studies, in which the actual outcome probabilities cannot be estimated (40) . Since it is based exclusively on ranks, however, it measures only how well the predicted values can rankorder the responses. It may not be as sensitive as the likelihood function in choosing between models, especially when the models are strong (28) . This may be particularly true in settings where many individuals fall into low-risk groups, as is true of cardiovascular risk detection in the general population as well as in the WHS. In the current data, the c-index could not distinguish between blood pressure, smoking, or any of the measured blood predictors, even though the likelihood ratio statistics clearly ordered variable contributions, with systolic blood pressure being the strongest predictor after age. In fact, hsCRP was a stronger individual predictor than any of the lipid measures in these data, including HDL cholesterol, its closest competitor. Thus, reliance solely on the c-statistic for model development could erroneously lead to the exclusion of lipids as well as hsCRP from risk prediction models. Accuracy, or the predictive ability of a model, has 2 major components, discrimination and calibration (28) . The c-statistic is a measure of discrimination, or the ability to separate 2 groups, such as case-patients and controls. Particularly in a prospective study, calibration, or how well the predicted probabilities reflect actual risk, is another aspect of accuracy not captured by the c-statistic. A model could discriminate well but lack even internal calibration if the fitted scores do not reflect the true probability of an event. The predicted probability given the risk factors, or the post-test probability, can be more useful clinically in assessing future cardiovascular risk than sensitivity or specificity, on which the c-statistic is based. Put another way, as Moons and Harrell have stated (41), sensitivity and specificity have no direct diagnostic meaning; for the patient, the issue is not the risk for having a positive test result, but the risk for developing the disease. In our data, the model that included hsCRP was better calibrated and was a better predictor of the probability of disease.
Clinically, the inclusion of hsCRP in global prediction models more accurately predicted true cardiovascular risk in these data. While it did not strongly affect estimated risk among women originally at very low risk, hsCRP had a substantial effect among women at 5% or higher 10-year risk. Among those classified as having 5% to less than 20% risk, the addition of hsCRP reclassified about 20% of women into more accurate risk strata. This would suggest that an effective clinical strategy to improve risk prediction might be to evaluate hsCRP among women with at least 5% predicted risk based on traditional risk factors.
One of the primary goals of any risk prediction algorithm for CVD is to identify individuals at increased risk who will benefit from aggressive lifestyle changes, including dietary moderation, exercise, and smoking cessation, all of which reduce hsCRP levels in addition to decreasing cardiovascular risk. Thus, knowledge of hsCRP level and more precise global risk estimation may help motivate patients to improve adherence to therapeutic lifestyle changes, as currently advocated in the ATP III guidelines (2) . Ten-year risks are also commonly estimated to make therapeutic decisions with regard to lipid-lowering therapy, particularly with statin agents. Previous research demonstrates that statin agents decrease hsCRP levels in a manner largely independent of LDL cholesterol, and the efficacy of statin therapy is linked in part to underlying hsCRP levels (42-46). As shown in our data, approximately 20% of individuals at "intermediate risk" had their risk estimates substantively increased or decreased with improved accuracy when hsCRP was added to the Framingham covariables. Thus, the use of an hsCRP-modified Framingham risk score also has the potential to help more patients and physicians to better direct the use of preventive statin therapy to appropriate risk groups.
Limitations of our analysis merit consideration. First, our analysis is limited to women, and thus care must be taken before these data are generalized to men. However, data from several other large cohorts of men have found hsCRP to predict risk independently of the traditional Framingham covariables (7, 9 -12, 14, 16, 47) . Second, our data are based on a single determination of hsCRP instead of 2 measures, as is currently recommended (21) . This limitation would tend to increase variability in our measures of hsCRP and thus lead, if anything, to an underestimation of true effects. Third, in contrast to LDL cholesterol, there remains no evidence to date that reducing hsCRP level itself will reduce cardiovascular risk. As such, although these data show that in women the addition of hsCRP can improve global risk prediction models, they should not be construed as implying a direct benefit of hsCRP reduction, an issue now being evaluated in several clinical trials. Finally, we evaluated only hsCRP in this study and recognize the possibility that other biomarkers of inflammation, hemostasis, and thrombosis may become available in the future. In this regard, we believe that the methods developed here to address incremental value for risk screening will be of use as other novel biomarkers emerge.
